Skip to main content

Garofalo Elizabeth A.'s Form 4 filing

Xenon Pharmaceuticals Inc.XENE · filed Mar 11, 2024

Accession no.
0000950170-24-029542
Filed
Mar 11, 2024
Trade date
Mar 8, 2024
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $95.6K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Garofalo Elizabeth A.CIK 0001826361Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 8, 2024Common SharesMOption exerciseAcquired+3,500$18.56+$64,9603,500Direct
Mar 8, 2024Common SharesFTax withholdingDisposed−1,408$46.16F1−$64,993.282,092Direct
Mar 8, 2024Common SharesSSaleDisposed−2,092$45.69−$95,583.480Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 8, 2024Common SharesMOption exerciseDisposed−20,000$0.00$016,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents the closing price of the Company's common shares on March 7, 2024 for purposes of net settlement calculations.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)